BBOT
BridgeBio Oncology Therapeutics Inc.
There isn't enough reported data to score BBOT yet.
BBOT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate BBOT's fundamentals.
BBOT PE Valuation
BBOT has no meaningful PE right now: it lost money over the past year.
BBOT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect BBOT's earnings, revenue and profitability to hold roughly steady.
BBOT Earnings Per Share
BBOT Quarterly Revenue
BBOT Free Cash Flow
BBOT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +131K shares |
BBOT Net Leverage
BBOT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BBOT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.1 | Oversold |
| Stochastic | 2.3 | Oversold |
BBOT's weekly RSI is 25 (oversold) and its Stochastic is 2 (oversold).
BBOT PE vs Healthcare Sector
BBOT has no meaningful PE right now: it lost money over the past year.
BBOT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.96 | 21% below |
| 20 week MA | $6.02 | 61% below |
| 50 week MA | $8.40 | 72% below |
BBOT is in a downtrend: it's below all three of its weekly moving averages, and 72% below its 50-week average.
BBOT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $10.1 | $12.3 | +23% |
| 2026 YTD | $12.3 | $2.35 | -81% |
BBOT has finished every year since 2025 higher, and it's down 81% so far in 2026.